STAT+: European Commission investigates Vifor for ‘disparaging’ its only rival in iron deficiency market

The European Commission has opened an investigation into allegations that Vifor Pharma spread misleading information about a rival treatment to its blockbuster drug for iron deficiency, the latest sign of governments cracking down on anticompetitive practices in the pharmaceutical industry.

In a statement, the EC explained that Vifor may have disparaged its “closet and, potentially, only” competitor to its Ferinject medicine in the European market. Specifically, the global drug company ran a “misleading communication campaign,” primarily targeting health care providers, about a treatment sold by Pharmacosmos, a small, family run company based in Denmark.

Continue to STAT+ to read the full story…